<DOC>
	<DOCNO>NCT02957617</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety tolerability BIIB074 participant neuropathic Pain From Lumbosacral Radiculopathy ( PLSR ) . A secondary objective investigate maintenance effect long-term treatment BIIB074 participant neuropathic PLSR . For efficacy assessment , baseline prior randomization Study 1014802-203 . Another secondary objective evaluate impact treatment BIIB074 quality life ( QoL ) .</brief_summary>
	<brief_title>Extension Study Evaluate Long-Term Safety , Tolerability , Maintenance Effect BIIB074</brief_title>
	<detailed_description>Convergence Pharmaceuticals , Ltd. , register England , acquire affiliate subsidiary Biogen , Inc . This extension study 1014802-203 .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Radiculopathy</mesh_term>
	<criteria>Key Has complete Study 1014802203 complete duration . Key Has meet exclusion criterion precede doubleblind Phase 2b study ( Study 1014802203 ) . Had protocol deviation regard inclusion exclusion criterion doubleblind Phase 2b study ( Study 1014802203 ) . Had treatmentrelated AE SAE would pose increase risk continue treatment BIIB074 , discontinue study treatment doubleblind Phase 2b study ( Study 1014802203 ) due AE SAE . Did return study visit discontinue treatment doubleblind phase Phase 2b study . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neuropathic Pain From Lumbosacral Radiculopathy , PLSR</keyword>
</DOC>